Trial Profile
Phase I Trial of Chemoradiation With Capecitabine and Vorinostat in Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary) ; Capecitabine
- Indications Biliary cancer; Pancreatic cancer
- Focus Adverse reactions
- 12 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 16 May 2013 Planned end date changed from 1 May 2015 to 1 Mar 2018 as reported by ClinicalTrials.gov.
- 16 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.